DOI:

Tryton Side-Branch Stent

Aaron V. Kaplan1,2*, M.D; H. Richard Davis2

Description

The Tryton Side-Branch Stent™ is a slotted tube balloon deployable stent with a modular design comprise of three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone (Figure 1).

Figure 1. Schematic representing the Tryton Side-Branch Stent showing three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone. When positioned correctly within the vasculture the Side-Branch Zone resides in the side-branch, Transition Zone at the side-branch origin and the Main Vessel Zone in the main vessel proximal to the side-branch origin.

Tryton performs like a standard high-performance workhorse stent, i.e., balloon expandable, tracking over a single wire and axially oriented without the need for rotational orientation. The Tryton is simply tracked over a guidewire placed in the side-branch, such that the transition zone is at the side-branch origin. To insure precise delivery, the Tryton Side-Branch Stent is mounted on a balloon with four shaft markers, 2 standard proximal/distal stent markers, and 2 additional markers delineating the Transition Zone. The Tryton Stent is deployed after which the guidewire initially placed in the side-branch is repositioned into the distal main vessel. The Tryton stent is compatible with any standard workhorse stent (bare metal or DES), which is tracked into the Main Vessel Zone of the Tryton Stent and between specially designed fronds exiting into the distal main vessel stent (Figure 2).

Figure 2. Schematic representing the spacial relationship between the Tryton Side-Branch Stent (deployed) with an undeployed main vessel stent. The distal end of the main vessel stent has been tracked through the proximal Main Vessel Zone of the Tryton Stent, between the specially designed fronds and into the distal main vessel.

The main vessel stent is deployed after which a kissing balloon inflation is performed. Employing this strategy provides a means to definitively treat bifurcation lesions with similar coverage and hoop strength currently available with state of the art stents used in straight lesions (Figure 3).

Figure 3. Photograph of a Tryton Side-Branch Stent deployed in a plexiglass model in combination with a Cypher Stent (Cordis/ Johnson&Johnson, Miami, FL) using the protocol outlined within main text.

History

Tryton Medical, Inc. is a privately held company with offices in Newton, Massachusetts, USA founded to develop devices to treat bifurcation lesions within the coronary, cerebral and peripheral circulations.

Volume 2 Number 2
Aug 20, 2006
Volume 2 Number 2
View full issue


Key metrics

Suggested by Cory

Trial Design

10.4244/EIJ-D-25-00486 Sep 30, 2025
Mechanical circulatory support in high-risk elective PCI: rationale and design of the PROTECT IV trial
Mangner N et al
free

Editorial

10.4244/EIJ-E-25-00022 Sep 15, 2025
An ongoing quest to discern the optimal antithrombotic therapy after TAVI
Hayashida K and Iwata J
free

Research Correspondence

10.4244/EIJ-D-25-00255 Sep 15, 2025
Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves
Tarantini G et al

Editorial

10.4244/EIJ-E-25-00038 Sep 15, 2025
Evolving cutoff values for optimising left main stenting with intravascular imaging
de la Torre Hernandez J
free

Original Research

10.4244/EIJ-D-24-01066 Sep 15, 2025
VARC-HBR criteria validation in TAVI patients on oral anticoagulation
Overduin D et al

Translational research

10.4244/EIJ-D-24-01000 Sep 15, 2025
DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI
Meier D et al
open access

Flashlight

10.4244/EIJ-D-25-00121 Sep 15, 2025
Calcium mapping by 3DStent technology
Amabile N and Benamer H
Trending articles
96.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
67.15

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved